Stryker Spine Putty Approval “Significantly” Delayed, Firm Says
This article was originally published in The Gray Sheet
Executive Summary
FDA is requesting additional data to support Stryker's OP-1 Putty PMA, which could delay approval of the posterolateral lumbar spine fusion surgery indication until 2009, the firm says
You may also be interested in...
Orthopedic Devices Panel Rejects Stryker’s OP-1 Putty For Spinal Fusion
FDA's Orthopedic and Rehabilitation Devices advisory panel voted 6-1 to recommend against approval of Stryker Biotech's OP-1 Putty spinal fusion product March 31
Orthopedic Devices Panel Rejects Stryker’s OP-1 Putty For Spinal Fusion
FDA's Orthopedic and Rehabilitation Devices advisory panel voted 6-1 to recommend against approval of Stryker Biotech's OP-1 Putty spinal fusion product March 31
Ortho Earnings: Stryker Plans Big Compliance Investment In 2009
Stryker will spend between $60 million and $90 million on compliance initiatives in 2009, as it overhauls its quality standards and resolves issues related to three outstanding FDA warning letters